The Technical Analyst
Arcutis Biotherapeutics [ARQT]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Arcutis Biotherapeutics Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: BUY (auto-tracking)
-1.40% $8.47
America/New_York / 26 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 973.80 mill |
| EPS: | -3.78 |
| P/E: | -2.24 |
| Earnings Date: | May 07, 2024 |
| SharesOutstanding: | 114.97 mill |
| Avg Daily Volume: | 4.30 mill |
| RATING 2024-04-26 |
|---|
| B- |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Sell | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Strong Sell | |
| DE: | Strong Buy | |
| P/E: | Sell | |
| Price To Book: | Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | |||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -2.24 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.38x |
| Company: PE -2.24 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$-1.716 (-120.26%) $-10.19 |
| Date: 2024-04-26 |
| Expected Trading Range (DAY) |
|---|
|
$ 7.55 - 9.39 ( +/- 10.85%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-04-10 | Topper David Joseph | Buy | 310 000 | Stock Option (right to buy) |
| 2024-04-10 | Topper David Joseph | Buy | 110 000 | Common Stock |
| 2024-04-10 | Topper David Joseph | Sell | 7 500 | Stock Option (right to buy) |
| 2024-03-04 | Matsuda Masaru | Sell | 3 760 | Common Stock |
| 2024-03-04 | Burnett Patrick | Sell | 4 782 | Common Stock |
| INSIDER POWER |
|---|
| 30.76 |
| Last 98 transactions |
| Buy: 3 267 821 | Sell: 1 662 580 |
Forecast:
16:00 - $8.47
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $8.47
Forecast 2: 16:00 - $8.47
Forecast 3: 16:00 - $8.47
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $8.47 (-1.40% ) |
| Volume | 2.16 mill |
| Avg. Vol. | 4.30 mill |
| % of Avg. Vol | 50.31 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For ARQT
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:35 | sell | $5.66 | N/A | Active |
|---|
ARQT
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam formulation of roflumilast for the treatment of seborrheic dermatitis and scalp psoriasis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; and ARQ-255, a topical formulation of ARQ-252 designed to reach deeper into the skin in order to treat alopecia areata. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.
Latest Press Releases
2024-04-10 08:00:00 - Press Release
Arcutis Appoints David Topper As Chief Financial Officer
Westlake village, calif., april 10, 2024 (globe newswire) -- arcutis biotherapeutics, inc. (nasdaq: arqt), a commercial-stage company focused on developing meaningful innovations in immuno-dermatology, today announced that david topper has been appointed chief financial officer (cfo) effective april 10, 2024.
2024-04-05 16:00:00 - Press Release
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Westlake village, calif., april 05, 2024 (globe newswire) -- arcutis biotherapeutics, inc. (nasdaq: arqt), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported the grant of an aggregate of 58,500 restricted stock units of arcutis' common stock to four newly hired employees. these awards were approved by the compensation committee of arcutis' board of directors and granted under the arcutis biotherapeutics, inc. 2022 inducement plan, with a grant date of april 1, 2024, as an inducement material to the new employees entering into employment with arcutis, in accordance with nasdaq listing rule 5635(c)(4).
2024-03-28 08:00:00 - Press Release
Arcutis To Present At The 23rd Annual Needham Virtual Healthcare Conference
Arcutis today announced that arcutis management will participate in the 23rd annual needham virtual healthcare conference, taking place april 8-11, 2024.
2024-03-11 08:00:00 - Press Release
Arcutis Promotes Todd Tucker To Chief Human Resources Officer
Industry veteran with over 25 years' experience will continue to advance the company culture and grow the capabilities of arcutis' workforce westlake village, calif., march 11, 2024 (globe newswire) -- arcutis biotherapeutics, inc. (nasdaq: arqt), a commercial-stage company focused on developing meaningful innovations in immuno-dermatology, today announced the promotion of todd tucker to senior vice president and chief human resources officer (chro), effective immediately.
2024-03-10 16:00:00 - Press Release
Arcutis Presents Late-breaking Data From Integument-ped Phase 3 Trial Of Roflumilast Cream 0.05% In Atopic Dermatitis In Children Ages 2 To 5 At The American Academy Of Dermatology Annual Meeting
Investigational roflumilast cream 0.05% met the primary endpoint and all secondary endpoints, showing significant improvement across multiple efficacy endpoints as early as week 1 39.4% of children treated with roflumilast cream 0.05% achieved a 75% improvement in eczema area and severity index (easi-75), a key secondary endpoint new data highlight rapid and significant reduction in itch as early as 24 hours following first application of roflumilast cream 0.05% based on daily worst itch numeric scale (wi-nrs) new data show 35.4% of children treated with roflumilast cream 0.05% achieved a validated investigator global assessment – atopic dermatitis (viga-ad) score of ‘clear' or ‘almost clear' at week 4, with significant improvements seen as early as week 1 results for roflumilast cream 0...
Latest News
2024-03-28 08:00:00 - GlobeNewsWire
Arcutis to Present at the 23rd Annual Needham Virtual Healthcare Conference
Arcutis today announced that Arcutis management will participate in the 23rd Annual Needham Virtual Healthcare Conference, taking place April 8-11, 2024.
2024-03-19 10:56:10 - Zacks Investment Research
Arcutis Biotherapeutics, Inc. (ARQT) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
Arcutis Biotherapeutics, Inc. (ARQT) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
2024-03-18 10:56:03 - Zacks Investment Research
Wall Street Analysts See a 54.78% Upside in Arcutis Biotherapeutics, Inc. (ARQT): Can the Stock Really Move This High?
The average of price targets set by Wall Street analysts indicates a potential upside of 54.8% in Arcutis Biotherapeutics, Inc. (ARQT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
2024-03-01 10:56:11 - Zacks Investment Research
Wall Street Analysts See a 58.85% Upside in Arcutis Biotherapeutics, Inc. (ARQT): Can the Stock Really Move This High?
The consensus price target hints at a 58.9% upside potential for Arcutis Biotherapeutics, Inc. (ARQT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
2024-03-01 10:46:30 - Zacks Investment Research
Is Arcutis Biotherapeutics (ARQT) Outperforming Other Medical Stocks This Year?
Here is how Arcutis Biotherapeutics, Inc. (ARQT) and Athira Pharma, Inc. (ATHA) have performed compared to their sector so far this year.
2024-02-29 17:00:00 - GlobeNewsWire
Arcutis to Present at the TD Cowen 44th Annual Health Care Conference
WESTLAKE VILLAGE, Calif., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that Arcutis management will participate in the TD Cowen 44th Annual Health Care Conference.
2024-02-16 08:00:00 - GlobeNewsWire
Arcutis to Report Fourth Quarter and Full Year 2023 Financial Results
Arcutis today announced that it will report its fourth quarter and full year financial results and provide a business update on Tuesday, February 27, 2024.
2024-02-05 12:41:35 - InvestorPlace
3 Once-in-a-Lifetime Biotech Stocks With Unprecedented Surge Potential
The biotech sector is one of my favorite sectors since it is not only constantly growing and with companies that are always doing wonderful research, products, and solutions, but it is also a sector that is constantly innovating and contributing to the health of the human being. If you want to participate as an investor in this sector and take advantage of companies that have great growth opportunities, here are three biotech stocks with potential that you can consider adding to your portfolio.
2024-01-31 08:00:00 - GlobeNewsWire
Arcutis to Present at the Guggenheim Healthcare Talks – 6th Annual Biotechnology Conference
WESTLAKE VILLAGE, Calif., Jan. 31, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that Arcutis management will participate in the Guggenheim Healthcare Talks – 6th Annual Biotechnology Conference.
2024-01-31 03:09:25 - Seeking Alpha
Arcutis: Slow Sales Of Zoryve May Be Painting The Wrong Picture
